The shares of Infinity Pharmaceuticals Inc. (INFI) were up 8.11% to $2.4 in pre-market trading at the time of this writing. Monday’s session ended with INFI stock down -3.48% at $2.22. The volume for INFI stock was 4.75 million shares, a higher volume than the average daily volume of 2.07 million shares over the past 50 days.
INFI stock has appreciated by 167.47% over the past 12 months but has fallen by -17.47% over the past week. The INFI stock has lost -31.69% over the past three months, and -43.80% over the past six months. In addition, INFI has a current market cap of $216.49 million, with 75.73 million outstanding shares. INFI stock is rising on the chart today ahead of a webinar.
What will INFI Stock be presenting at the event?
Biotech company Infinity is developing eganelisib (IPI-549), an intravenous, macrophage reprogramming medication with the potential to be a first-in-class immuno-oncology treatment. A number of clinical trials have shown that INFI stock treatment addresses a fundamental biological mechanism that suppresses the immune system.
INFIS MARIO-275 is a randomized, controlled combination study that combines eganelisib with Opdivo for the treatment of urothelial cancer I/O naive patients. The INFI study MARIO-3 is the first combination study by INFI Stock to investigate eganelisib in front-line patients with advanced cancer.
This morning at 8 am Eastern Time, Infinity will host a webinar for key opinion leaders.
- INFI stock will discuss the MARIO-3 TNBC study and the MARIO-275 UC study, both of which add eganelisib to currently approved standard of care regimens.
- As part of the MARIO-3 trial, eganelisib will be added to the combined regimen of Tecentriq and Abraxane which is approved as the standard of care for TNBC in the front-line setting.
- The aim of MARIO-275 is to evaluate the addition of Eganelisib to approved standard of care Opdivo monotherapy in immuno-oncology-nave UC patients who have progressed on platinum therapy as a second line treatment.
- A presentation by Erika P. Hamilton, M.D. will be featured during the webinar.
- The latest data from MARIO-3, obtained by the Sarah Cannon Research Institute at Tennessee Oncology, will be discussed in relation to the current standard of care.
What will INFI’s webinar cover?
Following the formal presentation, Dr. Hamilton will be available to answer questions about preliminary MARIO-3 TNBC data in December 2020 at the 2020 San Antonio Breast Cancer Symposium. A status update on eganelisib in UC will be presented by Dr. Brian Schwartz, INFI Stock Consulting Chief Physician, based on preliminary data from the MARIO-275 Phase 2 study in second-line patients with UC. Dr. Schwartz’s presentation will be based on the data which he presented at the 2021 ASCO Genitourinary Cancers Symposium in February 2021 and will be available to answer questions following the formal presentation.
